For investors and healthcare operators

A replicable longevity medicine model, built with discipline.

We measure health with advanced tests and follow it over time. We do this in our own facilities and, above all, inside already-licensed clinics, with a model that requires little capital and can be repeated. A field already validated worldwide, still to be built properly in Italy.

Welcoming lounge of the longevity unit inside an already-licensed clinic
The model in brief
Hubin clinic
Little capital, replicable, disciplined
Inside already-licensed clinics
4points to understand what kind of operation this is
2components of the return: recurring flow and the value of the assets
3qualities of the model: little capital, replicable, disciplined
0public fundraising: a confidential and selective conversation

Amounts, scope and economic terms are in the confidential dossier, not on the public website.

The operation in plain terms

What kind of operation this is, in four points.

No public figures, but clear from the start: so you can tell whether this is your kind of operation. By "dossier" we mean the confidential documentation for investors.

What it isA co-investment in the facility and a selective partnership, not a public fundraising. The group puts in its own capital first; the order of magnitude of the commitment over time also includes the leverage of the subsidised Invitalia call and selective forms of co-investment in the facility, so it is not all the partners' risk capital.
What return it seeksTwo components: a recurring cash flow from the network of clinics, and the value of the assets built over time.
Where we areAt the launch stage. Today the strength is the model, the method and the people, not growth numbers to show off.
How to get accessBy qualified request: you write to us, we assess, and if there is alignment we give you access to the confidential dossier with figures and terms.

Amounts, scope and economic terms are in the confidential dossier, not on the public website.

The thesis, in brief

The thesis, in three lines.

Medicine is shifting from treating disease to prevention that can be measured. Demand for quality longevity services is growing steadily.

Today this demand is served poorly: one-off check-ups, aesthetics disguised as prevention, a fragmented offering, no continuity after the first report.

Longevilife brings three things together, tests and biomarkers, the history of the data over time, and a journey that continues, and takes them inside third-party clinics that are already licensed, with a model that can be repeated.

Why now

Three forces converging now.

Here the forces are described qualitatively. The numbers and sources, always attributed to third parties, are on the Market validation page.

Structural shift

Medicine is moving from treating disease to measurable prevention. It is a long-term change, not a fad.

Sector capital

International capital is concentrating on models of measurable longevity and scalable prevention.

Scientific maturity

Biomarkers and indicators validated on large cohorts now make a serious method possible, not promises.

The numbers and sources are on the Market validation page.

The model, in concrete terms

Who brings what.

The heart of the thesis is not a single centre, but a model that enters inside already-licensed clinics (we call "Hub" the longevity unit inside an already-active clinic). This avoids much of the capital and time of building a clinic from scratch, and the model can be repeated.

Longevilife bringsThe partner clinic brings
Brand and methodExisting spaces and equipment
Clinical protocols and trainingDoctors and medical responsibility
Dedicated people and operational managementBilling of the services
Patient acquisition and nutraceuticalsAuthorisations already in place

Example of what the end client receives: a first complete measurement (tests and biomarkers), a journey built on their data, and re-tests over time to compare results and adjust course, not a one-off check-up.

Why it works

The three qualities of the model.

Little capital for investors

It relies on authorisations and clinical spaces that already exist, instead of building them from scratch. For us and for the clinic, entry costs less and arrives sooner.

Replicable

A defined format, repeatable across multiple facilities without reinventing it each time.

Disciplined

A method based on evidence and communication without exaggerated promises: what lets a serious doctor put their name to it.

We write it the way we think it: today what counts is the model, the method and the people, not growth numbers to show off.

Automated laboratory pipettor supporting the longevity model
Confidential conversation
For strategics, groups and funds

For healthcare groups and strategic operators.

If you represent a healthcare group, a sector operator or a fund considering a strategic position, the Longevilife model is designed to integrate with networks of already-existing clinics and to grow by opening new Hubs one after another. We open a confidential and selective conversation, on a basis of mutual acquaintance.

  • Integrates with networks of already-existing clinics.
  • Grows by opening new Hubs one after another.
Governance

A project led by people, not by promises.

A team with clinical, scientific and development expertise. The governance distinguishes two roles: scientific direction (scientific vision, method and protocols) and an independent medical direction to be appointed, registered with the medical board, with clinical responsibility for the facility. This way the clinical role stays separate from the business role. Names and roles of the team are in the confidential material.

The complete dossier is confidential.

Thesis, model, figures for each type of facility and the scope of the project are in a dossier that we share on qualified request. Access is manual and selective.